LENSAR (NASDAQ:LNSR) vs. Sanara MedTech (NASDAQ:SMTI) Financial Contrast

Sanara MedTech (NASDAQ:SMTI – Get Free Report) and LENSAR (NASDAQ:LNSR – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Analyst Ratings

This is a summary of recent recommendations for Sanara MedTech and LENSAR, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sanara MedTech 1 4 0 0 1.80
LENSAR 1 0 2 0 2.33

Sanara MedTech presently has a consensus price target of $35.00, indicating a potential upside of 6.84%. LENSAR has a consensus price target of $11.00, indicating a potential upside of 107.94%. Given LENSAR’s stronger consensus rating and higher probable upside, analysts clearly believe LENSAR is more favorable than Sanara MedTech.

Risk and Volatility

Sanara MedTech has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, LENSAR has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.

Institutional & Insider Ownership

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 40.1% of LENSAR shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by insiders. Comparatively, 65.8% of LENSAR shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Sanara MedTech and LENSAR’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sanara MedTech -2.69% 32.45% 3.21%
LENSAR 56.07% 1,254.25% 49.13%

Earnings & Valuation

This table compares Sanara MedTech and LENSAR”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sanara MedTech $103.12 million 2.92 -$37.56 million ($0.35) -93.60
LENSAR $58.44 million 1.11 -$34.28 million ($0.40) -13.22

LENSAR has lower revenue, but higher earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than LENSAR, indicating that it is currently the more affordable of the two stocks.

Summary

LENSAR beats Sanara MedTech on 10 of the 14 factors compared between the two stocks.

About Sanara MedTech

(Get Free Report)

Sanara MedTech, Inc. develops, markets and distributes medical products for wound care, surgical tissue repair and related applications. Its offerings are intended for use by healthcare professionals treating acute and chronic wounds and supporting tissue healing. The company’s portfolio includes CellerateRX® collagen-based products and BIAK?S® antimicrobial products, along with other solutions for wound and surgical care. Sanara sells its products to healthcare providers and through distribution channels.

About LENSAR

(Get Free Report)

LENSAR, Inc. develops and markets laser-based technology for ophthalmic surgery, with a focus on procedures used to treat cataracts. Its systems are designed to assist surgeons with key steps in cataract surgery, including the creation of incisions and the fragmentation of the eye’s natural lens. The company’s products include the ALLY Adaptive Cataract Treatment System and the LENSAR Laser System, which use imaging and software to support surgical planning and treatment. LENSAR also offers related software, accessories and services for ophthalmic practices and surgical facilities.

Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.